Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer?

Print
Published on Wednesday, 20 December 2017

Abstract

OBJECTIVES: Salivary gland impairment after high-dose radioiodine (¹³¹I) treatment is well recognized. The aim of this study was to determine the protective effect of vitamin E on radiation-induced salivary gland dysfunction in patients undergoing ¹³¹I treatment for differentiated thyroid cancer.

METHODS: Thirty-six patients with differentiated thyroid carcinoma were enrolled in this study. They were randomly divided into two groups before postsurgical ablation therapy with 3700-5550 MBq ¹³¹I: the control group, comprising 17 patients, and the vitamin E group, comprising 19 patients. All 19 patients in the experimental group received vitamin E at a dose of 800 IU/day for a duration of 1 week before to 4 weeks after I therapy and the 17 patients in the control group received a placebo for the same duration. Salivary gland function was assessed using salivary gland scintigraphy with intravenous injection of 370 MBq Tc-pertechnetate in two phases, one immediately before and the other 6 months after ¹³¹I ablative therapy. First-minute uptake ratio, maximum uptake ratio, maximum secretion percentage, and excretion fraction (EF) of each salivary gland were measured and compared between the study phases for the two groups.

RESULTS: There was no significant difference between preablative and postablative salivary scintigraphic indices in the experimental vitamin E group, whereas maximum secretion percentage and EF of the right submandibular gland and EF of the left parotid gland were significantly decreased in the control group. There was also a higher significant decrease in the EF of the left parotid gland in the control group compared with the vitamin E group.

CONCLUSION: Vitamin E consumption may be associated with a significant protective effect against radiation-induced dysfunction in salivary glands following single-dose ¹³¹I therapy in patients with differentiated thyroid cancer.

 

 

About this publication.

 

See also:

- Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;

- All-Trans-Retinoic Acid (ATRA - analogues and/or derivatives);

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck.